Prima Biomed Ltd (PBMD) 1.19 $PBMD
Prima BioMed's CVac(TM) Granted Fast Track Designation by FDA
Marketwire - Fri May 09, 6:01AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima"
is pleased to announce today that the United States Food and Drug Administration ("FDA" granted Fast Track Designation to the CVac clinical development program at Prima. This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission. Prima will work closely with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the U.S.
Prima BioMed Third Quarter Conference Call
Marketwire - Tue Apr 29, 8:54AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company" today released its Appendix 4C - Quarterly Report for the three month period ending 31 March 2014. The Company had A$26,737,000 in cash and term deposits as of the end of the quarter. The majority of funds spent during the quarter are related to development activities of Prima's lead product CVac(TM).
Prima BioMed's CAN-004 Phase 2 Trial for CVac(TM) Commences Recruitment
Marketwire - Mon Apr 28, 8:33AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" today announced that enrolment has commenced for its amended phase 2 CAN-004 clinical trial in Europe for its therapy candidate CVac for the treatment of ovarian cancer.
Prima BioMed to Present at 13th Annual Needham Healthcare Conference
Marketwire - Sun Apr 06, 8:30PM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company" today announced that its Chief Executive Officer, Matthew Lehman, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. U.S. Eastern time (corresponds to Thursday, April 10 at 4:20 a.m. in Sydney) in New York City. Mr. Lehman will provide a Company overview and update on recent activities.
Prima BioMed's CVac(TM) Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO
Marketwire - Thu Mar 27, 8:40PM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" announced today that the American Society of Clinical Oncology has accepted the abstract entitled, "Progression-free survival in ovarian cancer patients in second remission is improved with mucin-1 autologous dendritic cell therapy" for oral presentation at the Gynecologic Cancer Session at the 2014 ASCO Annual Meeting to be held May 30 - June 3, 2014 in Chicago.
Prima BioMed Announces Significant Updates to Its Clinical Advisory Board: Eric Pujade-Lauraine, Christian Marth, and Ignace Vergote Join Esteemed Group of Gynecology Oncology Advisors
Marketwire - Tue Mar 25, 8:39AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company" announced today that Professors Eric Pujade-Lauraine, MD, PhD, Christian Marth, MD, PhD, and Ignace Vergote MD, PhD have joined Prima's Clinical Advisory Board to advise on the Company's development of CVac(TM) for the treatment of epithelial ovarian cancer. These esteemed researchers and clinicians join Prima's existing clinical advisory board members Jonathon Berek and Bradley Monk in the United States, Walther Kuhn in Germany, and Jeffrey Goh in Australia.
$1.6 Million R&D Tax Incentive Refund Received
Marketwire - Wed Mar 05, 8:26AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company" is pleased to advise that it has received approximately $1.6 million in cash rebate from the Australian federal government's R&D tax incentive program. The cash rebate was provided essentially in respect of expenditure incurred on eligible Australian R&D activities conducted on the CVac clinical trials during the 2013 financial year.
Global Psoriasis Drug Forecast and Market Analysis to 2022 - Sales by region
M2 - Thu Feb 27, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/bkkwwm/pharmapoint) has announced the addition of the "PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022" report to their offering. 2012 PsO drug sales to be $5.6 billion across the nine major markets (9MM) covered in this report: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By forecast end in 2022, sales will increase to over $7.62 billion at a Compound Annual Growth Rate (CAGR) of 3.1%, which includes seven pipeline therapies and the launch of biosimilars. This growth will be driven by: - The launch of novel PsO products, such as Eli Lilly's ixekizumab, Amgen's brodalumab, Novartis' secukinumab, Merck's MK-3222, Pfizer's Xeljanz (tofacitinib), Celgene's apremilast, and Biocon's Alzumab (itolizumab) - The uptake of biosimilars for the currently marketed biologics: etanercept, adalimumab, infliximab, and ustekinumab - Increased access to PsO biologics in China and India Despite these drivers, the PsO market will be crowded, yet comprised of diversified therapies. Individual drugs will struggle to gain a foothold as they distinguish themselves from each other. Unmet Needs in Psoriasis While dermatologists agree that the current biologics have revolutionized the PsO landscape, there is a dire need for therapies that can provide long-lasting effects, without side effects or an increased risk of comorbidities. The current pipeline includes at least four novel therapies that have exceptionally high clinical efficacy and good safety profiles, and these include: Novartis' secukinumab, Amgen's brodalumab, Merck's MK-3222, and Eli Lilly's ixekizumab. The dosing schedule for these therapies is quite convenient, as some of them are dosed once monthly and four times a year on average. Interestingly, of the seven pipeline products, three are me-too biologics, each of which targets the cytokine interleukin-17 (IL-17). However, we expect Novartis' inhibitor to be the first of this group to launch in 2014. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AbbVie (Abbott) - Johnson & Johnson - Novartis - Pfizer - Eli Lilly - Merck - LEO Pharma - Celgene For more information visit http://www.researchandmarkets.com/research/bk...harmapoint
Prima BioMed to Present at Regen Med Investor Day March 26th in New York
Marketwire - Wed Feb 26, 7:15PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company" will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
Prima BioMed to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 4:30PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company" will present a corporate overview and provide an update of its CVac(TM) development program at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York City on Monday, March 3rd at 1:35 p.m. (U.S. Eastern Standard Time).
Prima BioMed enters into final license agreement for CVac with Neopharm Group in Israel and the Palestinian Authority
M2 - Fri Feb 21, 4:46AM CST
Therapeutic products company Prima BioMed (ASX
RR) (NASDAQ BMD) said on Thursday that it has finalised its exclusive agreement to license, market and sell CVac in Israel and the Palestinian Authority, for the treatment of epithelial ovarian cancer.
Prima BioMed and Neopharm Group Execute Final Agreement for CVac License
Marketwire - Thu Feb 20, 4:09PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" is pleased to announce that it has finalized an agreement with Neopharm Group ("Neopharm" for an exclusive license ("License" to market and sell CVac(TM), a personalized immunocellular therapeutic under investigation for the treatment of epithelial ovarian cancer, in Israel and the Palestinian Authority.
Prima BioMed names Dr Bradley J. Monk to clinical advisory board
M2 - Thu Feb 20, 9:11AM CST
Immunocellular therapeutic company Prima BioMed Ltd (ASX RR) (NASDAQ BMD) reported on Wednesday the addition of Dr Bradley J. Monk, MD, to its clinical advisory board, with responsibility for the development of CVac for the treatment of epithelial ovarian cancer.
Dr. Bradley J. Monk to Join Prima BioMed's Clinical Advisory Board
Marketwire - Wed Feb 19, 6:05PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company" announced today that Bradley J. Monk, MD, an esteemed clinical researcher and practicing gynecological oncologist, has joined Prima's Clinical Advisory Board to advise the Company's development of CVac(TM) for the treatment of epithelial ovarian cancer.
Prima BioMed Ltd names Pete A Meyers to board
M2 - Wed Feb 12, 3:09AM CST
Therapeutic company Prima BioMed Ltd (ASX RR) (NASDAQ BMD) revealed on Tuesday the addition of Pete A Meyers as non-executive director of the board with immediate effect.
Pete A. Meyers to Join Prima BioMed's Board of Directors
Marketwire - Tue Feb 11, 5:45PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company" is pleased to announce that Pete A. Meyers will join Prima's Board as a Non-Executive Director with immediate effect.
Prima BioMed's CAN-004 Clinical Trial Amendment Approved in Multiple Jurisdictions
Marketwire - Wed Feb 05, 4:00PM CST
Prima BioMed Ltd. (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company" announced that multiple jurisdictions have approved its amended CAN-004 protocol including regulators in Latvia, Lithuania, Bulgaria, Ukraine and Belarus. As previously announced, the CAN-004 trial was approved by the Belgian regulators in January 2014.
Source Exploration Corp. Announces Adoption of Advance Notice-By-Law and Retains Transcend Resource Group for Investor Relations Services
Marketwire Canada - Mon Feb 03, 12:52PM CST
Source Exploration Corp. (the "Corporation" (TSX VENTURE:SOP) today announced that its board of directors (the "Board" has approved an amendment to the by-laws of the Corporation (By-Law No. 1) to include mandatory procedures for nominations of persons for election to the Board, including an advance notice requirement for nominations of directors by shareholders in certain circumstances (the "By-Law Amendment" .
Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference
Marketwire - Thu Jan 30, 8:20PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company" has announced today that Matthew Lehman, its Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, 10 February 2014 in New York City at the Waldorf Astoria Hotel. Mr. Lehman will provide an overview of the Company and its corporate activities and will be available to participate in one-on-one meetings.
Prima BioMed Second Quarter Highlights and Management Conference Call
Marketwire - Wed Jan 29, 7:05AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company" today released its Appendix 4C - Quarterly Report for the second quarter of financial year 2014, the three month period ending 31 December 2013.
Prima BioMed's CVac(TM) Granted Fast Track Designation by FDA
Marketwire - Fri May 09, 6:01AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima"
is pleased to announce today that the United States Food and Drug Administration ("FDA" granted Fast Track Designation to the CVac clinical development program at Prima. This program is intended to improve overall survival in patients with relapsed platinum-sensitive epithelial ovarian cancer who enter a second complete remission. Prima will work closely with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the U.S. Prima BioMed Third Quarter Conference Call
Marketwire - Tue Apr 29, 8:54AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company"
today released its Appendix 4C - Quarterly Report for the three month period ending 31 March 2014. The Company had A$26,737,000 in cash and term deposits as of the end of the quarter. The majority of funds spent during the quarter are related to development activities of Prima's lead product CVac(TM). Prima BioMed's CAN-004 Phase 2 Trial for CVac(TM) Commences Recruitment
Marketwire - Mon Apr 28, 8:33AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima"
today announced that enrolment has commenced for its amended phase 2 CAN-004 clinical trial in Europe for its therapy candidate CVac for the treatment of ovarian cancer. Prima BioMed to Present at 13th Annual Needham Healthcare Conference
Marketwire - Sun Apr 06, 8:30PM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company"
today announced that its Chief Executive Officer, Matthew Lehman, will present at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. U.S. Eastern time (corresponds to Thursday, April 10 at 4:20 a.m. in Sydney) in New York City. Mr. Lehman will provide a Company overview and update on recent activities. Prima BioMed's CVac(TM) Data Demonstrating Improvement in PFS in Second Remission Ovarian Cancer Accepted for Oral Presentation at ASCO
Marketwire - Thu Mar 27, 8:40PM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima"
announced today that the American Society of Clinical Oncology has accepted the abstract entitled, "Progression-free survival in ovarian cancer patients in second remission is improved with mucin-1 autologous dendritic cell therapy" for oral presentation at the Gynecologic Cancer Session at the 2014 ASCO Annual Meeting to be held May 30 - June 3, 2014 in Chicago. Prima BioMed Announces Significant Updates to Its Clinical Advisory Board: Eric Pujade-Lauraine, Christian Marth, and Ignace Vergote Join Esteemed Group of Gynecology Oncology Advisors
Marketwire - Tue Mar 25, 8:39AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company"
announced today that Professors Eric Pujade-Lauraine, MD, PhD, Christian Marth, MD, PhD, and Ignace Vergote MD, PhD have joined Prima's Clinical Advisory Board to advise on the Company's development of CVac(TM) for the treatment of epithelial ovarian cancer. These esteemed researchers and clinicians join Prima's existing clinical advisory board members Jonathon Berek and Bradley Monk in the United States, Walther Kuhn in Germany, and Jeffrey Goh in Australia. $1.6 Million R&D Tax Incentive Refund Received
Marketwire - Wed Mar 05, 8:26AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company"
is pleased to advise that it has received approximately $1.6 million in cash rebate from the Australian federal government's R&D tax incentive program. The cash rebate was provided essentially in respect of expenditure incurred on eligible Australian R&D activities conducted on the CVac clinical trials during the 2013 financial year. Global Psoriasis Drug Forecast and Market Analysis to 2022 - Sales by region
M2 - Thu Feb 27, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/bkkwwm/pharmapoint) has announced the addition of the "PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022" report to their offering. 2012 PsO drug sales to be $5.6 billion across the nine major markets (9MM) covered in this report: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By forecast end in 2022, sales will increase to over $7.62 billion at a Compound Annual Growth Rate (CAGR) of 3.1%, which includes seven pipeline therapies and the launch of biosimilars. This growth will be driven by: - The launch of novel PsO products, such as Eli Lilly's ixekizumab, Amgen's brodalumab, Novartis' secukinumab, Merck's MK-3222, Pfizer's Xeljanz (tofacitinib), Celgene's apremilast, and Biocon's Alzumab (itolizumab) - The uptake of biosimilars for the currently marketed biologics: etanercept, adalimumab, infliximab, and ustekinumab - Increased access to PsO biologics in China and India Despite these drivers, the PsO market will be crowded, yet comprised of diversified therapies. Individual drugs will struggle to gain a foothold as they distinguish themselves from each other. Unmet Needs in Psoriasis While dermatologists agree that the current biologics have revolutionized the PsO landscape, there is a dire need for therapies that can provide long-lasting effects, without side effects or an increased risk of comorbidities. The current pipeline includes at least four novel therapies that have exceptionally high clinical efficacy and good safety profiles, and these include: Novartis' secukinumab, Amgen's brodalumab, Merck's MK-3222, and Eli Lilly's ixekizumab. The dosing schedule for these therapies is quite convenient, as some of them are dosed once monthly and four times a year on average. Interestingly, of the seven pipeline products, three are me-too biologics, each of which targets the cytokine interleukin-17 (IL-17). However, we expect Novartis' inhibitor to be the first of this group to launch in 2014. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AbbVie (Abbott) - Johnson & Johnson - Novartis - Pfizer - Eli Lilly - Merck - LEO Pharma - Celgene For more information visit http://www.researchandmarkets.com/research/bk...harmapoint
Prima BioMed to Present at Regen Med Investor Day March 26th in New York
Marketwire - Wed Feb 26, 7:15PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company"
will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City. Prima BioMed to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 4:30PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company"
will present a corporate overview and provide an update of its CVac(TM) development program at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York City on Monday, March 3rd at 1:35 p.m. (U.S. Eastern Standard Time). Prima BioMed enters into final license agreement for CVac with Neopharm Group in Israel and the Palestinian Authority
M2 - Fri Feb 21, 4:46AM CST
Therapeutic products company Prima BioMed (ASX
RR) (NASDAQ BMD) said on Thursday that it has finalised its exclusive agreement to license, market and sell CVac in Israel and the Palestinian Authority, for the treatment of epithelial ovarian cancer. Prima BioMed and Neopharm Group Execute Final Agreement for CVac License
Marketwire - Thu Feb 20, 4:09PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
is pleased to announce that it has finalized an agreement with Neopharm Group ("Neopharm" for an exclusive license ("License" to market and sell CVac(TM), a personalized immunocellular therapeutic under investigation for the treatment of epithelial ovarian cancer, in Israel and the Palestinian Authority. Prima BioMed names Dr Bradley J. Monk to clinical advisory board
M2 - Thu Feb 20, 9:11AM CST
Immunocellular therapeutic company Prima BioMed Ltd (ASX
RR) (NASDAQ BMD) reported on Wednesday the addition of Dr Bradley J. Monk, MD, to its clinical advisory board, with responsibility for the development of CVac for the treatment of epithelial ovarian cancer. Dr. Bradley J. Monk to Join Prima BioMed's Clinical Advisory Board
Marketwire - Wed Feb 19, 6:05PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima," "the Company"
announced today that Bradley J. Monk, MD, an esteemed clinical researcher and practicing gynecological oncologist, has joined Prima's Clinical Advisory Board to advise the Company's development of CVac(TM) for the treatment of epithelial ovarian cancer. Prima BioMed Ltd names Pete A Meyers to board
M2 - Wed Feb 12, 3:09AM CST
Therapeutic company Prima BioMed Ltd (ASX
RR) (NASDAQ BMD) revealed on Tuesday the addition of Pete A Meyers as non-executive director of the board with immediate effect. Pete A. Meyers to Join Prima BioMed's Board of Directors
Marketwire - Tue Feb 11, 5:45PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
is pleased to announce that Pete A. Meyers will join Prima's Board as a Non-Executive Director with immediate effect. Prima BioMed's CAN-004 Clinical Trial Amendment Approved in Multiple Jurisdictions
Marketwire - Wed Feb 05, 4:00PM CST
Prima BioMed Ltd. (ASX: PRR) (NASDAQ: PBMD) ("Prima," the "Company"
announced that multiple jurisdictions have approved its amended CAN-004 protocol including regulators in Latvia, Lithuania, Bulgaria, Ukraine and Belarus. As previously announced, the CAN-004 trial was approved by the Belgian regulators in January 2014. Source Exploration Corp. Announces Adoption of Advance Notice-By-Law and Retains Transcend Resource Group for Investor Relations Services
Marketwire Canada - Mon Feb 03, 12:52PM CST
Source Exploration Corp. (the "Corporation"
(TSX VENTURE:SOP) today announced that its board of directors (the "Board" has approved an amendment to the by-laws of the Corporation (By-Law No. 1) to include mandatory procedures for nominations of persons for election to the Board, including an advance notice requirement for nominations of directors by shareholders in certain circumstances (the "By-Law Amendment" . Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference
Marketwire - Thu Jan 30, 8:20PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company"
has announced today that Matthew Lehman, its Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Monday, 10 February 2014 in New York City at the Waldorf Astoria Hotel. Mr. Lehman will provide an overview of the Company and its corporate activities and will be available to participate in one-on-one meetings. Prima BioMed Second Quarter Highlights and Management Conference Call
Marketwire - Wed Jan 29, 7:05AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company"
today released its Appendix 4C - Quarterly Report for the second quarter of financial year 2014, the three month period ending 31 December 2013. 
